![\"Persistence](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/10\/1759860310_330_960x0.jpg\")
<\/p>\n<\/p>\n
Green Plant Growing Out Of Crack In Concrete – Persistence Concept<\/p>\n
getty<\/p>\n
The cannabis sector has endured a dramatic correction. After peaking<\/a> at a combined valuation of roughly $37 billion in 2021, leading publicly traded cannabis companies (Curaleaf, Green Thumb, Tilray and Trulieve) are now worth less than $11 billion (as of October 7, 2025).<\/p>\n Oversupply, plunging wholesale prices (average U.S. retail cannabis prices have fallen<\/a> 32% since 2021), heavy debt burdens, stalled federal reforms and punitive tax treatment under IRS code 280E have left many operators cash-strapped. In parallel, more than $3.8 billion in delinquent payments<\/a> are weighing on the ecosystem, with invoices averaging about 1.6 months (~6\u20137 weeks) past due.<\/p>\n Complicating matters further, hemp regulations remain unsettled. More than 30 states have banned or restricted intoxicating hemp-derived cannabinoids<\/a> like delta-8 THC and Congress is considering closing the \u201chemp loophole\u201d<\/a> in the 2025 Farm Bill. These pressures have eroded margins and investor confidence across the industry.<\/p>\n Yet, it is not all contraction. Select operators, both private and public, continue to expand nationally by focusing on capital discipline, measured growth and diversified strategies.<\/p>\n Author\u2019s note\/disclosure: This article draws on a mix of company-supplied data (for private operators) and public filings (for listed firms). Figures have been reviewed for accuracy but are not independently audited or intended as investment-grade research. They are presented for industry context only. I do not own, nor do I plan to buy or sell, shares in any of the companies mentioned within 1 week before or after publication.<\/p>\n Industry Context And Consolidation<\/p>\n The collapse has forced both investors and advisors to rethink what sustainable growth in cannabis looks like.<\/p>\n Seth Yakatan, an investor and longtime industry advisor, cautions against the idea that mergers alone will save struggling operators. \u201cDe-leveraging must occur and profitable growth must occur. Catalyst states still provide upside,\u201d he said in an interview.<\/p>\n But the barriers are structural. Legal operators, Yakatan noted, remain hemmed in by the illicit market and limited household penetration. He estimates California\u2019s legal market at about $4 billion annually, with the illicit trade of similar size. Pointing to Hoodie Analytics\u2019 benchmark of roughly $800 in annual household spend for cannabis, he added that if California hit that level of penetration, \u201cthe market could approach $12 billion.\u201d<\/p>\n Sandy Li, a partner at Viridian Capital Advisors, echoed that survival depends less on size and more on strategy. \u201cThe brands still earning consumer loyalty are those that invested in differentiation,\u201d she said. \u201cWith flower increasingly commoditized, it is not enough to compete on price. Instead, companies are holding ground by focusing on quality, authentic storytelling, consistent customer experiences and innovation.\u201d<\/p>\n ForbesAmerica\u2019s $3.1 Billion Cannabis Pre-Roll Habit: 316 Million Joints Smoked Last Year\u2014Here\u2019s Who Cashed InBy Javier Hasse<\/a><\/p>\n That dynamic is especially visible in certain categories. \u201cInfused pre-rolls, solventless concentrates, edibles and beverages are all capturing share,\u201d Li added. \u201cFor example, according to Hoodie Analytics, unit sales of pre-rolls has exceeded vape unit sales in the U.S. for the first time. The global edibles market alone is expected to grow from $14.8 billion in 2024 to $48.7 billion by 2030. Products featuring CBN, CBG and other cannabinoids are expanding the consumer base beyond recreational users, with wellness-focused categories projected to grow at ~22% CAGR through 2030.\u201d<\/p>\n Policy Tailwinds Offer Limited Relief<\/p>\n Even as operators retrench, federal policy remains a critical (and unpredictable) variable. The industry is still waiting for clarity on rescheduling: moving cannabis from Schedule I to Schedule III would reduce the crushing burden of IRS Code 280E and unlock research pathways.<\/p>\n President Donald Trump has also hinted at a different, health-framed approach. In late September, he reposted<\/a> a polished video urging Medicare coverage of hemp-derived CBD, calling it \u201cthe most important senior health initiative of the century.\u201d The post sent cannabis stocks jumping, a reminder of how closely investors are watching Washington for signals. For many, it suggested Trump may view cannabis reform less through a cultural or criminal-justice lens and more through healthcare cost savings, a path that could prove politically safer.<\/p>\n What Rescheduling And 280E Relief Could Change<\/p>\n Still, industry advisors caution that no single policy change will erase the sector\u2019s structural challenges. Yakatan sees rescheduling as helpful but limited. \u201cFor those in pure retail, this will help a lot, as if 280E goes away, they get a 20%-ish lift to profits,\u201d he said. He noted that many MSOs have accrued 280E liabilities and may not see a dramatic near-term change in cash flow, while product companies may experience less impact. \u201cIt helps, but I am not sure it is the magic wand that wipes away the sins of too many debts and not enough profits.\u201d<\/p>\n Yakatan added that hemp remains an open question: \u201cMy crystal ball is dark on how legal changes will manifest.\u201d<\/p>\n ForbesLegal Weed Is Working, Data Suggests: $24.7 Billion In Taxes, Teen Use Down In Most StatesBy Javier Hasse<\/a><\/p>\n Li agreed that the sector must avoid chasing headlines. In her words, three fundamentals remain non-negotiable: \u201ctracking gross margin per unit, tightening working capital management and enforcing strict cost controls.\u201d She warned that expansion for its own sake is no longer rewarded and stressed that \u201cevery dollar of Capex needs a clear, near-term path to return.\u201d<\/p>\n Private Operators Expanding Strategically<\/p>\n Not all cannabis companies are shrinking. A handful of private operators continue to grow, largely by emphasizing discipline, niche strategies and diversification.<\/p>\n Sun Theory<\/p>\n Austin-based Sun Theory has expanded from one state in 2021 to multiple states today, with revenue rising from $2.8 million in 2021 to nearly $30 million in 2024. The company projects $70 million in revenue for 2025, spanning dispensaries, hemp and cannabis manufacturing, and consumer wellness brands.<\/p>\n In August 2025, Sun Theory ranked<\/a> No. 644 on the Inc. 5000 list of America\u2019s fastest-growing private companies, reflecting more than 650% growth since 2021. CEO Connor Oman said the company prioritizes profit over scale: \u201cWe enter only those jurisdictions where the rules are intelligible and the margin structure is attractive. That means focusing on asset-light, brand-driven businesses while sidestepping the risks of large-scale cultivation.\u201d<\/p>\n Sun Theory reports EBITDA margins above 40%, a gross margin of 66%, and consistent cash distributions to limited partners. It has also signaled international ambitions, targeting Europe, Australia and South Africa.<\/p>\n Bud & Mary\u2019s<\/p>\n Midwestern operator Bud & Mary\u2019s has taken a different path, focusing on research-driven cultivation and sustainability. According to internal company data, revenues grew from $9.3 million in 2020 to $24.8 million in 2024. By mid-2025, revenue stood at $12.3 million, putting the company on track to at least match prior-year performance.<\/p>\n Units sold nearly doubled over four years, from 438,000 in 2020 to almost 960,000 in 2024. Market tracker Hoodie ranked Bud & Mary\u2019s fourth in Colorado sales in late 2024; by mid-2025, it had climbed to the number two spot.<\/p>\n True Terpenes<\/p>\n Growth is not limited to plant-touching operators. Oregon-based True Terpenes has scaled by positioning itself as an ancillary supplier focused on diversification and resilience. CEO Daniel Cook explained: \u201cThere\u2019s no single point of failure in our model, and that\u2019s by design. The cannabis market is too volatile to bet on one path, so we focus on resilience through diversification. We keep our innovation pipeline full, tracking trends in taste, aroma and function to help our clients stand out.\u201d<\/p>\n Cook added that True Terpenes \u201coperates where sensory science and hedonics meet market relevance,\u201d and highlighted that its toxicology work has been adopted by ASTM as part of its global standards framework. Looking across the downturn, Cook sees ancillary companies as bellwethers for the broader market: \u201cWe power over $8 billion worth of the most exciting cannabis products each year, giving us a unique vantage point into what\u2019s actually working across form factors, cultivars and sensory trends.\u201d<\/p>\n He emphasized reliability as a competitive edge: \u201cWe\u2019re shipping our innovations in 0.7 days on a 2-day SLA, consistently. That reliability gives our clients a competitive advantage.\u201d<\/p>\n ForbesThis One Decision Could Cost America Up To $10 Billion A Year, According To ExpertsBy Javier Hasse<\/a>Signs of Resilience: Cannabis Companies On The 2025 Inc. 5000<\/p>\n The Inc. 5000 list provides a snapshot of private companies showing rapid growth, even in cannabis, though it can sometimes reflect expansion from small bases. Several cannabis-linked firms earned spots in 2025, proving that growth is still achievable despite industry-wide pressure:<\/p>\n Still, Seth Yakatan cautioned against reading too much into ancillary momentum: \u201cMany of the businesses in this vertical exist only because of the constraints which are placed upon the cannabis sector. As such many of them have a long-term sustainable competitive advantage for durable growth. If or when the walls fall down more established companies will enter the fray. Tell me Oracle or Net Suite, Visa or Mastercard do not show up the day the walls fall down?\u201d<\/p>\n Yakatan also pointed to a list of brands he sees executing well despite the headwinds \u2014 from Stiiizy<\/a> and Embarc to Wyld, Kiva, Jeeter and Uncle Arnie\u2019s \u2014 while stressing that long-term success will come down to profitability and discipline.<\/p>\n Key Considerations<\/p>\n These examples highlight that growth is possible, but it comes with caveats: many of the fastest-growing firms are scaling from small bases and sustainability remains unproven. Against that backdrop, a few large public operators have still managed to post real gains.<\/p>\n Public Companies Maintaining Growth<\/p>\n While private players are carving new paths, a handful of publicly traded operators continue to show measured growth. Their financials highlight how rare, and fragile, expansion can be in today\u2019s market.<\/p>\n Green Thumb Industries<\/p>\n Chicago-based Green Thumb Industries (GTI) remains one of the largest U.S. multi-state operators, with more than 100 dispensaries in 14 states and 20 cultivation-manufacturing facilities.<\/p>\n In 2024, the company generated $1.1 billion in revenue, up 7.8% from 2023, according to its annual report<\/a>. While many peers have reported losses, GTI has remained cash-flow-positive, supported by a disciplined capital expenditure strategy. Its RISE retail chain spans states from Nevada to Minnesota, positioning the company to benefit from new adult-use rollouts.<\/p>\n In Q1 2025, GTI reported $280 million in revenue, essentially flat versus the prior year, while in Q2 revenue grew 4.7% year-over-year to $293.3 million<\/a>, with $56 million in operating cash flow. GTI has shown resilience, maintaining cash-flow positivity while peers have reported steep losses, though its growth has been incremental rather than explosive.<\/p>\n Trulieve<\/p>\n Trulieve reported<\/a> full-year 2024 revenue of $1.2 billion, up ~5% year-over-year, driven by a 5% quarterly gain and record cash flow from operations.<\/p>\n In Q1 2025, the company maintained<\/a> momentum, generating $298 million in revenue, achieving 62% gross margin, and producing $51 million in operating cash flow. In Q2, it posted $302 million in revenue with adjusted EBITDA up year over year.<\/p>\n Still, the gains have been moderate, and like peers, Trulieve remains vulnerable to pricing pressure and federal uncertainty.<\/p>\n Vireo Growth And Deep Roots Harvest<\/p>\n In June 2025, Minnesota-based Vireo Growth completed a $132.7 million acquisition of Nevada operator Deep Roots Harvest<\/a>, part of a broader $397 million multi-state consolidation.<\/p>\n Vireo reported<\/a> fiscal 2024 revenue of $99.4 million, up 15.4% YoY and ended the year with $91.6 million in cash.<\/p>\n In Q1 2025, it posted $24.5 million in revenue<\/a> a modest 1.9% increase, while pro forma projections for Q2 (post-merger) called for $90.7 million in revenue and $23.2 million in adjusted EBITDA<\/a>. Yet, much of its 2025 momentum comes from acquisitions, underscoring both opportunity and execution risk.<\/p>\n Author\u2019s note: These examples, however, are the exception rather than the rule in an industry where most operators remain under severe stress.<\/p>\n\n